MX2010009844A - Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento. - Google Patents

Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento.

Info

Publication number
MX2010009844A
MX2010009844A MX2010009844A MX2010009844A MX2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A MX 2010009844 A MX2010009844 A MX 2010009844A
Authority
MX
Mexico
Prior art keywords
ziprasidone
human
kits
dosage forms
cns disorder
Prior art date
Application number
MX2010009844A
Other languages
English (en)
Spanish (es)
Inventor
Dwayne Thomas Friesen
Jaymin Chandrakant Shah
William John Curatolo
Scott Max Herbig
Avinash Govind Thombre
Sheri L Shamblin
Timothy LUKAS
William Brett Caldwell
David Keith Lyon
Christopher Donovan Craig
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2010009844A publication Critical patent/MX2010009844A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010009844A 2008-03-07 2009-03-04 Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento. MX2010009844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3494708P 2008-03-07 2008-03-07
PCT/IB2009/000442 WO2009109844A1 (en) 2008-03-07 2009-03-04 Methods, dosage forms, and kits for administering ziprasidone without food

Publications (1)

Publication Number Publication Date
MX2010009844A true MX2010009844A (es) 2010-09-30

Family

ID=40720011

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009844A MX2010009844A (es) 2008-03-07 2009-03-04 Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento.

Country Status (15)

Country Link
US (1) US20110002989A1 (OSRAM)
EP (1) EP2280711A1 (OSRAM)
JP (1) JP2009215293A (OSRAM)
KR (1) KR20100131477A (OSRAM)
CN (1) CN102014910A (OSRAM)
AR (1) AR070964A1 (OSRAM)
AU (1) AU2009220925A1 (OSRAM)
BR (1) BRPI0909818A2 (OSRAM)
CA (1) CA2719115A1 (OSRAM)
IL (1) IL207792A0 (OSRAM)
MX (1) MX2010009844A (OSRAM)
RU (1) RU2010135831A (OSRAM)
TW (1) TW200950783A (OSRAM)
WO (1) WO2009109844A1 (OSRAM)
ZA (1) ZA201005905B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010082855A1 (en) * 2009-01-15 2010-07-22 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
US9510148B2 (en) * 2009-03-03 2016-11-29 Mobilitie, Llc System and method for wireless communication to permit audience participation
KR102337598B1 (ko) * 2013-05-03 2021-12-10 신닥스 파마슈티컬스, 인크. 암 치료 방법
MX2016001304A (es) 2013-07-30 2016-04-07 Gilead Connecticut Inc Polimorfo de inhibidores de syk.
PT3027171T (pt) 2013-07-30 2020-06-18 Gilead Connecticut Inc Formulação de inibidores da syk
WO2015082562A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US10474345B2 (en) * 2014-04-04 2019-11-12 Shawn SHEY User interfaces and methods for displaying content
AU2015317468B2 (en) * 2014-09-19 2018-06-14 The Procter & Gamble Company Process for making a core with an active coating
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
CA2987081C (en) 2015-06-11 2022-08-30 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
CN107714669A (zh) * 2016-08-11 2018-02-23 广东东阳光药业有限公司 齐拉西酮缓释剂及其制备方法
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
WO2005065660A2 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Ziprasidone formulations
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
EP1901722A4 (en) * 2005-06-20 2011-06-15 Elan Pharma Int Ltd NANOTEHOUS COMPOSITIONS WITH CONTROLLED RELEASE FROM ARYL-HETEROCYCLIC COMPOUNDS

Also Published As

Publication number Publication date
RU2010135831A (ru) 2012-04-20
AR070964A1 (es) 2010-05-19
EP2280711A1 (en) 2011-02-09
WO2009109844A1 (en) 2009-09-11
JP2009215293A (ja) 2009-09-24
BRPI0909818A2 (pt) 2015-10-06
CA2719115A1 (en) 2009-09-11
AU2009220925A1 (en) 2009-09-11
TW200950783A (en) 2009-12-16
CN102014910A (zh) 2011-04-13
US20110002989A1 (en) 2011-01-06
IL207792A0 (en) 2010-12-30
KR20100131477A (ko) 2010-12-15
ZA201005905B (en) 2011-11-30

Similar Documents

Publication Publication Date Title
MX2010009844A (es) Procedimientos, formas farmaceuticas, y kits para administrar ziprasidona sin alimento.
MX2010008720A (es) Composiciones, metodos y estuches para mejorar la respuesta inmunitaria a una enfermedad respiratoria.
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
MX2009011949A (es) Inhibidores de proteina activadora de 5-lipoxigenasa (flap).
MX2010003884A (es) Anticuerpo dirigido a la proteina lecitina similar a inmunoglobulina de union a acido sialico-15 relacionado con osteoclastos.
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
MY156316A (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
PT1957061E (pt) Combinação compreendendo, pelo menos, um aminoácido e um inibidor de pkr para utilização no tratamento da perda muscular
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
WO2012145651A3 (en) Compounds for the treatment of neuropsychiatric disorders
MX2010002410A (es) Metodo para proveer los beneficios de energia, alivio del estres y mejora del estado de animo, que comprende administrar una composicion que comprende colecalciferol y un extracto de te.
GB0001449D0 (en) Compositions
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
Vieyra-Reyes et al. Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression
WO2009140416A3 (en) Treatment for epilepsy
MX2009003518A (es) Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
WO2008007227A3 (en) Method and compositions for relieving menopausal and perimenopausal symptoms
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2010001116A (es) Derivados novedosos de benzamidina, proceso para la preparacion de estos y composicion farmaceutica para la prevencion o el tratamiento de osteoporosis que comprende a los mismos.
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
EP1830814A4 (en) TASTE SUPPRESSION SYSTEM FOR NON-WEIGHTED MEDICINAL PRODUCTS
BRPI0503827A (pt) métodos para prevenir ou tratar infecções respiratórias em lactentes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal